ZA201004671B - Aldh-2 inhibitors in the treatment of addiction - Google Patents
Aldh-2 inhibitors in the treatment of addictionInfo
- Publication number
- ZA201004671B ZA201004671B ZA2010/04671A ZA201004671A ZA201004671B ZA 201004671 B ZA201004671 B ZA 201004671B ZA 2010/04671 A ZA2010/04671 A ZA 2010/04671A ZA 201004671 A ZA201004671 A ZA 201004671A ZA 201004671 B ZA201004671 B ZA 201004671B
- Authority
- ZA
- South Africa
- Prior art keywords
- aldh
- addiction
- inhibitors
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/051862 WO2009094028A1 (en) | 2008-01-24 | 2008-01-24 | Aldh-2 inhibitors in the treatment of addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201004671B true ZA201004671B (en) | 2011-03-30 |
Family
ID=39731733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/04671A ZA201004671B (en) | 2008-01-24 | 2010-07-02 | Aldh-2 inhibitors in the treatment of addiction |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2254878A1 (en) |
| JP (1) | JP2011510072A (en) |
| KR (1) | KR20100130589A (en) |
| CN (1) | CN101925590A (en) |
| AU (1) | AU2008348372A1 (en) |
| BR (1) | BRPI0822129A2 (en) |
| CA (1) | CA2712750A1 (en) |
| EC (1) | ECSP10010417A (en) |
| IL (1) | IL207127A0 (en) |
| MA (1) | MA32095B1 (en) |
| MX (1) | MX2010008111A (en) |
| WO (1) | WO2009094028A1 (en) |
| ZA (1) | ZA201004671B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102161648A (en) * | 2011-02-18 | 2011-08-24 | 中国药科大学 | Preparation method and applications of isoflavone type compounds with selective estrogen receptor modulating activity |
| TWI567061B (en) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | Compounds for the treatment of addiction |
| AR087700A1 (en) * | 2011-08-30 | 2014-04-09 | Gilead Sciences Inc | ALDH-2 INHIBITORS IN ADDICTION TREATMENT |
| WO2019079209A1 (en) * | 2017-10-16 | 2019-04-25 | Amygdala Neurosciences, Inc. | Combination therapy for preventing addiction |
| CN108276374B (en) * | 2018-03-29 | 2020-01-31 | 天津科技大学 | Flavonoid aromatase inhibitor and preparation method and application thereof |
| CN110922394B (en) * | 2019-11-21 | 2021-04-06 | 中国科学院宁波材料技术与工程研究所 | Bio-based intrinsic flame-retardant epoxy resin precursor based on natural flavonoid compound and preparation method and application thereof |
| WO2023235753A2 (en) * | 2022-05-31 | 2023-12-07 | University Of Maryland, Baltimore | Aldh2 inhibitors and methods of use thereof |
| WO2023244584A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
| WO2023244563A1 (en) | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU162377B (en) * | 1970-05-27 | 1973-02-28 | ||
| US4166862A (en) * | 1971-05-25 | 1979-09-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Animal feed containing anabolic isoflavones |
| GB8626344D0 (en) * | 1986-11-04 | 1986-12-03 | Zyma Sa | Bicyclic compounds |
| US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| EP1077697B1 (en) * | 1998-05-12 | 2006-07-19 | The Endowment For Research In Human Biology, Inc. | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| JP4933730B2 (en) * | 2001-05-04 | 2012-05-16 | パラテック ファーマシューティカルズ インコーポレイテッド | Transcription factor modulating compounds and methods of use thereof |
| AUPR957001A0 (en) * | 2001-12-19 | 2002-01-24 | Novogen Research Pty Ltd | Isoflavone conjugates, derivatives thereof and therapeutic methods involving same |
| EP1542675A4 (en) * | 2002-06-27 | 2008-11-19 | Endowment For Res In Human Bio | Compounds useful for the inhibition of aldh |
| JP2008504292A (en) * | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | Immune enhancement compounds |
| PL377180A1 (en) * | 2005-09-21 | 2007-04-02 | Instytut Farmaceutyczny | Application of isoflavones and their derivatives in Mucopolysacharidose treatment |
| MX2008015765A (en) * | 2006-07-27 | 2009-03-26 | Cv Therapeutics Inc | Aldh-2 inhibitors in the treatment of addiction. |
| KR20100097675A (en) * | 2007-11-06 | 2010-09-03 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Aldh-2 inhibitors in the treatment of psychiatric disorders |
-
2008
- 2008-01-24 AU AU2008348372A patent/AU2008348372A1/en not_active Abandoned
- 2008-01-24 CA CA2712750A patent/CA2712750A1/en not_active Abandoned
- 2008-01-24 MX MX2010008111A patent/MX2010008111A/en not_active Application Discontinuation
- 2008-01-24 WO PCT/US2008/051862 patent/WO2009094028A1/en active Application Filing
- 2008-01-24 JP JP2010544284A patent/JP2011510072A/en active Pending
- 2008-01-24 EP EP08713963A patent/EP2254878A1/en not_active Withdrawn
- 2008-01-24 KR KR1020107016579A patent/KR20100130589A/en not_active Application Discontinuation
- 2008-01-24 CN CN200880125439XA patent/CN101925590A/en active Pending
- 2008-01-24 BR BRPI0822129-4A patent/BRPI0822129A2/en not_active IP Right Cessation
-
2010
- 2010-07-02 ZA ZA2010/04671A patent/ZA201004671B/en unknown
- 2010-07-21 IL IL207127A patent/IL207127A0/en unknown
- 2010-08-23 MA MA33106A patent/MA32095B1/en unknown
- 2010-08-23 EC EC2010010417A patent/ECSP10010417A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2712750A1 (en) | 2009-07-30 |
| JP2011510072A (en) | 2011-03-31 |
| AU2008348372A1 (en) | 2009-07-30 |
| KR20100130589A (en) | 2010-12-13 |
| IL207127A0 (en) | 2010-12-30 |
| CN101925590A (en) | 2010-12-22 |
| WO2009094028A1 (en) | 2009-07-30 |
| MA32095B1 (en) | 2011-02-01 |
| BRPI0822129A2 (en) | 2015-06-23 |
| MX2010008111A (en) | 2010-11-30 |
| ECSP10010417A (en) | 2010-11-30 |
| EP2254878A1 (en) | 2010-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL195400A0 (en) | Aldh-2 inhibitors in the treatment of addiction | |
| IL230683A0 (en) | Dpp-iv inhibitors for use in the treatment of nafld | |
| IL208354A0 (en) | Methods of treatment | |
| EP2361089A4 (en) | Compositions and methods for the treatment of altered -synuclein function | |
| IL212348A0 (en) | Treatment method | |
| EP2200977A4 (en) | F1f0-atpase inhibitors and related methods | |
| EP2308884A4 (en) | Method for producing -hetero-substituted alkylhalohydrosilane and use thereof | |
| IL213619A0 (en) | Treatment | |
| GB0802116D0 (en) | Treatment | |
| EP2300011A4 (en) | Therapeutic methods and compounds | |
| IL207127A0 (en) | Aldh-2 inhibitors in the treatment of addiction | |
| HK1149933A1 (en) | Diazacarbazoles and methods of use | |
| GB0819280D0 (en) | Imgaing and radiotherapy methods | |
| IL209548A0 (en) | Diazacarbazoles and methods of use | |
| GB0822011D0 (en) | Treatment | |
| GB0807018D0 (en) | Antibodies and treatment | |
| GB0811992D0 (en) | Treatment | |
| GB0918601D0 (en) | Decahydro-1H-Indenoquinolinone and decahydro-3H-cyclopenaphenanthridinone CYP17 inhibitors | |
| IL208611A0 (en) | Device and process for the formation of microdepositions | |
| HK1199729A1 (en) | Aldh-2 inhibitors in the treatment of addiction aldh-2 | |
| EP2164494A4 (en) | Methods of treatment | |
| HK1167406A1 (en) | Pyrazolone-derivatives and their use as pd4 inhibitors pd4 | |
| EP2512504A4 (en) | Treatment composition and method | |
| GB0820972D0 (en) | Treatment | |
| GB0805912D0 (en) | Treatment |